BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Wednesday reported a loss of $56 million in its third quarter.

On a per-share basis, the Boulder, Colorado-based company said it had a loss of 39 cents.

The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.

The biopharmaceutical company posted revenue of $30.7 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $34.8 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLVS at https://www.zacks.com/ap/CLVS

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News